Trial Profile

A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Delafloxacin (Primary) ; Aztreonam; Linezolid; Vancomycin
Indications Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
Focus Therapeutic Use
Sponsors Melinta Therapeutics

Most Recent Events

17 Dec 2015 Results published in the Journal of Antimicrobial Chemotherapy
06 Sep 2012 Results were presented in a late-breaking abstract at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), according to a Rib-X Pharmaceuticals media release.
16 Dec 2011 Primary endpoint 'Clinical-cure-rate' has been met for delafloxacin versus vancomycin

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com